Catalyst to file FDA request soon for increase to maximum Firdapse dose
Catalyst Pharmaceuticals is on track to submit an application requesting an increase to the maximum recommended daily dose of Firdapse (amifampridine) — its approved treatment for Lambert-Eaton myasthenic syndrome (LEMS) — from 80 to 100 mg. Currently, the maximum daily dosage of Firdapse is 80 mg for…